Abstract: Objective To investigate that whether the immuno-modulatory capacity is intact in CML patients bone marrow derived MSCs and what are the differences compare with those from normal donors. Methods Isolate MSCs from CML patients and normal donors respectively and exam their differences on the T lymphocyte proliferation by MLR, on the T lymphocyte cycle and apoptosis using flow cytometry. Results The results show that there is no obvious difference on the immunophenotype between MSCs from CML and normal donors, respectively. However, for the MSCs from CML patients, the capacity of suppressing T cell proliferation as well as G0/G1 phase (CML MSC:74.5%±1.2%;BMSC:94.0%±1.9%, p<0.05) is weakened, while the capacity of suppressing T cell apoptosis is enhanced (CML MSC:8.36%±1.31%; BMSC:14.1%±0.65%, p<0.05). Conclusion We propose that MSCs from pathological environment might be abnormal and should not be used for autologous transplantation.

Key words: Chronic Myeloid Leukemia, Mesenchymal Stem Cell, immuno-modulatory